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Purpose: We designed our study to evaluate the hypothesis that gastric cancer is correlated with iodine deficiency or thyroid dysfunction.
Materials and Methods: We investigated the total body iodine reserve, thyroid function status and autoimmune disorder in 40 recently 
diagnosed gastric adenocarcinoma cases versus 80 healthy controls. The participants came from a region with high gastric cancer rate 
but sufficient iodine supply due to salt iodination. The investigation included urine iodine level, thyroid gland clinical and ultrasonograph-
ic examination, and thyroid function tests.
Results: Goiter was detected more frequently in the case group (P=0.001); such a finding, however, was not true for lower than normal 
urine iodine levels. The free T3 mean level was significantly lower in the case group compared to the control group (P=0.005). 
Conclusions: The higher prevalence of goiter rather than low levels of urinary iodine in gastric adenocarcinoma cases suggests that goi-
ter, perhaps due to protracted but currently adjusted iodine deficiency, is more likely to be associated with gastric adenocarcinoma com-
pared to the existing iodine deficiency itself.
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Introduction
Well-known risk factors for gastric adenocarcinoma include ge-
netic and environmental factors like positive family history of gas-
tric cancer, low consumption of fruit and vegetables, high intake of 
salted, smoked or poorly preserved foods, smoking cigarettes and 
being infected with Helicobacter pylori.1,2 Recent comparative epi-
demic studies in different regions suggest iodine deficiency as a re-
movable cause of gastric adenocarcinoma, breast and thyroid cancer 
as it emphasized by “Venturi hypothesis”.3-8 Other studies suggested 
a possible link between overall thyroid abnormalities, other than 
inappropriate iodine intake, and gastric adenocarcinoma.9-11
The thyroid gland is, embryogenically and phylongenetically, 
derived from the primitive gut and thyroid follicular cells have gas-
troenteric origin.12 The stomach and the thyroid share many mor-
phological and functional similarities including iodine-concentrat-
ing capacity probably because of common embryologic origin.12-16 
It is possible that iodine in vertebrates, competes with free radicals 
as an antioxidant to bind the membrane lipids, proteins, and DNA 
to stabilize them.8 
In 1994, in accordance with Universal Salt Iodization campaign, 
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a government act prohibited manufacturing and trading of non-
iodized salt in all Iranian provinces (including Gorgan province, 
where the study took place). National consensus indicated that the 
diet of more than 90% of Iranian population had been supplement-
ed with iodized salt by year 2000. It also reported that goiter was 
hyperendemic in 20 provinces of the country (including Gorgan 
which was a division of Mazandaran province at that era) in 1989 
but the prevalence declined by 23~40% in the same provinces by 
2001.17
Two distinct hypotheses have been investigated by several 
previous studies. The first one suggests a nutritional or an envi-
ronmental parameter, iodine deficiency, as a predisposing factor 
for gastric adenocarcinoma. On the other hand, second hypothesis 
based on a positive correlation between different types of thyroid 
diseases and gastric adenocarcinoma, concludes that common em-
bryological origin of two organs may play the essential role.
We designed a case-control study, to investigate the frequency 
of both thyroid disorders and iodine deficiency in a group of pa-
tients with gastric adenocarcinoma compared to their matched 
controls. 
Materials and Methods
1. Population and sampling
We performed a case-control study including 40 cases and 80 
controls which were enrolled from a region with high incidence 
of gastric adenocarcinoma and a history of iodine deficient diet 
compensated after introducing supplementary iodine during recent 
years. All the cases were selected from recently diagnosed gastric 
adenocarcinoma patients based on their pathological biopsy samples 
obtained by endoscopy. All clinical and laboratory tests in our study 
were done prior to surgical resection or other major therapeutic ap-
proaches for the cases. The staging and grading of adenocarcinoma 
was not considered in the study. These patients did not have a his-
tory of receiving usual anti H. pylori treatments (triple or quadriple 
drugs) or a long history of taking antacids.
The controls were enrolled from the neighbors of the patients 
who voluntarily participated in the study; we enrolled the controls 
approximately at the same time course when our patients were 
diagnosed with their cancer and joined the study (year 2006 and 
2007); they were native people from Gorgan province which were 
selected from the neighbours of the patients (1 or 2 houses around) 
in the same range of age and sex (every 2 persons of the control 
group with the least possible age gaps from each person in the case 
group) to achieve the most probable socioeconomic and lifestyle 
similarity. None of them suffered from other types of cancer or 
received treatment for major gastrointestinal problems including 
H. pylori infection. None of the participants was a known case of 
hypo or hyperthyroidism prior to this study.
The study was conducted regarding the principles of the Decla-
ration of Helsinki and was approved by the Ethical Committee of 
the Golestan Research Center of Gastroenterology and Hepatology 
(IRB No. g/p/35/2700 on 15.08.2006). All the participants were in-
formed and signed a written consent before entering the study. 
2. Method
The participants completed a written questionnaire and were 
examined clinically by a trained physician. Thereafter, they under-
went blood and urine sampling and ultrasound examination. 
Serum levels of free T3, free T4, total T3, total T4, thyroid-
stimulating hormone (TSH) and antibody against thyroid peroxi-
dase (Anti-TPO) were measured using Kaveshiar kit by radioim-
munoassay. Ultrasound imaging of thyroid gland as well as the 
measurement of urine iodine levels was also conducted. 
The iodine level was measured in 24-hour urine collection 
samples of the participants using chemophotometric models.   
All the ultrasonographic exams for the participants including its 
size and the presence of any nodules were performed by a single 
radiologist. Thyroid volume in the range of 11±3 ml was consid-
ered normal.18 The ultrasound, rather than physical examination, 
was considered as the definite method to detect goiter. Diffuse and 
multinodular goiters were different types of goiter reported in our 
study. The enlarged size of the gland (more than 14 ml) was the 
main criteria for establishing the diagnosis of goiter; furthermore 
the presence of multinodular appearance was an inclusion criteria. 
Simple nodular gland, smaller than 14 ml was not considered as 
goiterous to avoid overestimation.
3. Statistical analysis
The data was analyzed using SPSS version 16 (SPSS Inc., Chi-
cago, IL, USA). We applied the descriptive c2 test (chi-square) to 
compare the incidence rate of goiter and the proportion of persons 
having lower than normal urine iodine level in the case and control 
groups (odds ratio with 95% confidence interval). After confirm-
ing the normal distribution of quantitative variables, the mean levels 
were compared using independent t-test. Nonparametric Mann-
Whitney U test was also used to compare variables not having 
normal distribution. P-values less than 0.05 were considered statis-




In this study we compared 40 gastric adenocarcinoma cases 
and 80 age and sex matched controls. Forty-two point five per-
cent of the cases and 43.8% of the controls were female. Twenty-
four members of the case group (60%) and 35 of the control group 
(43.8%) aged over 60 and the remainder were between 40 to 60 
years old; there was no significant difference between two groups 
regarding their age distribution (P=0.09).
Neither the cases nor the controls were known for thyroid 
problems or iodine deficiency in the past. The family history for 
thyroid diseases was also negative for all the participants. None of 
the participants had a history of taking anti H. pylori treatment.
The prevalence of diffuse or multinodular goiter was signifi-
cantly higher (P=0.001) in the case group (Table 1). In detail, 10 in-
dividuals in the case group (25%) versus 5 in the control (6.3%) had 
diffuse goiter. Multinodular goiter, on the other hand, was reported 
in only 3 cases (7.5%) whereas no one in the control group was re-
ported to have multinodular goiter. The mean thyroid gland volume 
was 11±8.2 in the case and 6.8±2.8 in the control group; there 
was a significant difference between the gland volume of these two 
groups (P=0.003).
Totally, 33 participants were detected to have at least one nod-
ule or cyst in their thyroid lobes; there was no significant differ-
ence between the frequency of affected individuals in two groups 
(P=0.39). 
There was no statistically significant difference between mean 
urine iodine levels two groups (P=0.074). Furthermore, 3 persons in 
the case group had urine iodine level lower than normal, while only 
one person in the control group was in this range. The difference 
between two groups was not significant (P=0.107) (Table 1).
Significant difference, was not shown between TSH, T4, T3 and 
free T4 mean levels of two groups (P-values 0.115, 0.993, 0.944, 
0.073 respectively). Mean free T3 levels were higher in the control 
group (P=0.003). The median serum levels of Anti-TPO was not 
significantly different between two groups (P=0.052). The median 
of this variable was used instead of its mean because of the absence 
of normal distribution (Table 1).
Discussion 
Iodide (I-) is an essential constituent of the thyroid hormones 
triiodothyronine (T3) and tetraiodothyronine (T4). A cornerstone 
of I- metabolism is active uptake of iodine in the thyroid, a process 
mediated by sodium/iodide symporter.14,15 I- is presumed to be ab-
sorbed in the small intestine and mainly excreted via the kidneys.15
Venturi et al.,4 reported in 1993 that iodine deficiency might 
represent a risk factor for gastric cancer and atrophic gastritis. Large 
studies in China and Poland demonstrated a correlation between 
iodine deficiency and incicence and mortality rate of gastric cancer 
reversible by iodine supplementation.3,6 Behrouzian and Aghdami.11 
showed that gastric cancer patients had lower, urine iodine/cre-
atinine ratio than controls. Kandemir et al.9 reported that 49% of 
gastric cancer cases versus 20% of controls had a positive history 
of goiter. Thyroid autoimmune diseases were also more frequently 
reported among the cases in this study. In contrast, Rossi et al.19 
failed to report any relation between having a positive history of 
various benign thyroid diseases and increased gastric cancer risk in 
Table 1. The differences between parameters obtained from patient (case) and healthy (control) groups
Major exposure Parameter Case group (SD) Control group (SD) P-value Odds ratio Normal range
Iodine deficiency 
related factors
Diffuse or multinodular goiter 
(frequency)
13 (32.50%) 5 (6.30%) 0.001 7.2 (2.4~22.2)
Low urine iodine level (frequency) 3 (7.50%) 1 (1.25%) 0.107 -
Urine iodine level (mean level) 20.13 (8.47) 23.06 (7.94) 0.072 - Less than 9.9 µg/dl
Thyroid function tests TSH (mean level) 2.18 (0.99) 1.87 (1.04) 0.115 - 0.4~6.1 mU/L
Total T3 (mean level) 1.60 (0.90) 1.59 (0.45) 0.944 - 0.52~1.85 nmol/dl
Free T3 (mean level) 1.95 (0.37) 2.20 (0.55) 0.003 - 1.6~3.7 pg/ml
Total T4 (mean level) 1.11 (24.58) 1.11 (25.91) 0.993 - 4.4~11.6 µg/dl
Free T4 (mean level) 1.21 (0.45) 1.32 (0.35) 0.073 - 0.86~1.78 ng/dl
Thyroid antibody Anti-TPO (median level) 16.57 (48.06) 5.63 (13.66) 0.052 - Less than 40 IU/ml
SD = standard deviation; TSH = thyroid-stimulating hormone; Anti-TPO = antibody against thyroid peroxidase. 
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a hospital-based case-control study in Italy. Other epidemiological 
studies have demonstrated a higher incidence of gastric cancer in 
the same geographical areas where iodine deficiency or excess have 
been reported.1 
Consistent with many other studies, we found a higher preva-
lence of goiter, either diffuse or nodular, in gastric adenocarcinama 
patients. However, similar to the study conducted by Kandemir et 
al.,9 we did not find a significant correlation between gastric ad-
enocinoma and hyper- or hypothyroidism based on TSH serum 
levels. In fact, euthyroid goiter was more frequent among gastric 
adenocarcinoma patients. Until 1990s the prevalence of goiter was 
the only indicator of iodine deficiency in population-based studies; 
however it might overestimate the problem because a long time is 
required for goiter to disappear following the supplementation of 
iodized salt. Therefore the test was replaced with urinary iodine, 
a more sensitive indicator of recent changes in iodine intake.20 
However, more recent studies conducted to evaluate the correla-
tion between gastric cancer and thyroid abnormalities reevaluated 
goiter as a better indicator of protracted iodine deficiency. Goiter 
also detected more accurately a previous iodine deficiency which is 
removed now following consumption of iodized salt.20,21
In contrast with Behrouzian and Aghdami, we did not find a 
statistically significant lower mean level of urine iodine in gastric 
adenocarcinoma cases compared to controls. One possible explana-
tion for this contradiction is the smaller size of our sample, which 
is also a limitation of our study. The calculated P-value, quite near 
the cut point (0.074), is also consistent with this explanation. We 
should also remind the incompetency of urine iodine level to detect 
recently adjusted iodine deficiencies. It is also possible that other 
goitrogens including polycyclic aromatic hydrocarbons and bacterial 
contamination of water supplies which are not necessarily associ-
ated with iodine deficiency have caused the gastric adenocarci-
noma.3,22
Analyzing thyroid function indices, we found lower mean 
level of free-T3 in case group compared to control group. Other 
tests like mean levels of total T4 and T3, and TSH were not sig-
nificantly different between two groups. Kandemir et al.9 did not 
find any significant correlation between gastric cancer and hypo 
or hyperthyroidism. Beletskaia23 reported an augmented total T3 
clearance in a review of the investigations designed to study T3 
pharmacokinetics under malignant tumors of the stomach and 
large intestine. Using an experimental extrathyroidal carcinogenesis 
model, Guernsey and Leuthauser24 reported that thyroid hormone 
is a very powerful co-factor and its mechanism of action might 
be via tumor suppressor genes. Our study did not show any sig-
nificant association between thyroid gland dysfunction and gastric 
adenocarcinoma. Significantly lower free-T3 mean level in the 
case group compared to the control group is attributable to the sick 
euthyroid syndrome which is commonly reported secondary to 
serious illnesses such as infections and malignancies specifically in 
their acute phase25; so this finding is not a reliable evidence for an 
exclusive association between thyroid gland dysfunction and gastric 
adenocarcinoma. Unfortunately we did not evaluate rT3, which is 
commonly tested in suspected cases of sick euthyroid syndrome.25
We also found that the median level of Anti-TPO was not 
significantly higher in our case group versus the control group al-
though the P-value was only a bit larger than the cut point (P=0.052). 
Furthermore, none of our participants had a history of autoimmune 
thyroid disease. Syrigos et al.10 reported that significantly more 
patients with gastric cancer suffered from autoimmune thyroid 
diseases compared to control subjects; Kandemir et al.9 also found 
more gastric cancer in patients with a history of self-reported 
thyroid autoimmune disease than their matched controls. Syrigos 
et al.10 measured anti thyroglobulin and antimicrosomal antibodies 
while the target antibody in our study was antiperoxidase antibody. 
It should be emphasized that gastric cells do not secrete thyroglob-
ulin while peroxidase activity is common in both thyroid and gas-
tric cells.16 The distribution of the amounts reported for anti-TPO 
was not normal, therefore the median value was calculated instead 
of its mean and this can confound the precision of the study. 
In conclusion, we demonstrated that iodine deficiency is more 
frequent in gastric adenocarcinoma cases compared to controls 
and this is not necessarily associated with thyroid dysfunction. Our 
study was a case-control survey which cannot basically find the 
etiology of the disorder, only suggesting an association between 
gastric adenocarcinoma and iodine deficiency. Consequently, fur-
ther cohort studies are required to indicate if iodine deficiency is a 
real etiologic factor for gastric adenocarcinoma or this association 
has more reasonable explanations. 
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